WO2024261701 - EDOXABAN FORMULATION.
National phase entry is expected:
Publication Number
WO/2024/261701
Publication Date
26.12.2024
International Application No.
PCT/IB2024/056059
International Filing Date
21.06.2024
Title **
[English]
EDOXABAN FORMULATION.
[French]
FORMULATION D'EDOXABAN.
Applicants **
INTAS PHARMACEUTICALS LTD.
Corporate House, Near Sola Bridge,
S. G. Highway, Thaltej, Ahmedabad - 380054,
Gujarat, India.
Ahmedabad 380054, IN
Inventors
PATEL, Piyush Babubhai
Intas Pharmaceuticals Ltd. – Astron Division
Plot 457/458, Sarkhej-Bavla Highway,
Matoda – 382210- Tal.: Sanand,
Ahmedabad.
Gujarat, India.
Ahmedabad 382210, IN
CHAUHAN, Manishkumar Jayantibhai
Intas Pharmaceuticals Ltd. – Astron Division
Plot 457/458, Sarkhej-Bavla Highway,
Matoda – 382210- Tal.: Sanand,
Ahmedabad.
Gujarat, India.
Ahmedabad 382210, IN
SEHGAL, Ashish
Intas Pharmaceuticals Limited - Astron Division
Plot No.: 457, 458, Vill.: Matoda, Sarkhej Bavla Highway Road,
Tal.: Sanand, Dist.: Ahmedabad - 382210, Gujarat, India.
Ahmedabad 382210, IN
Priority Data
202321041818
23.06.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| * | |
International Searching Authority |
IP India
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Translation |
|
Recalculate
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing | 961 | |
| EPO | Filing, Examination | 6330 | |
| Japan | Filing | 588 | |
| South Korea | Filing | 574 | |
| USA | Filing, Examination | 2710 |
Total: 11163 USD
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present invention is related to a pharmaceutical composition of edoxaban comprising edoxaban or its pharmaceutically acceptable salt thereof, water swelling additive and one or more pharmaceutical acceptable excipient, wherein the said formulation is devoid of sugar alcohol.[French]
La présente invention concerne une composition pharmaceutique d'edoxaban comprenant de l'edoxaban ou son sel pharmaceutiquement acceptable, un additif gonflant à l'eau et un ou plusieurs excipients pharmaceutiquement acceptables, ladite formulation étant exempte d'alcool de sucre.